499 related articles for article (PubMed ID: 34093569)
1. Can Resveratrol-Inhaled Formulations Be Considered Potential Adjunct Treatments for COVID-19?
Rossi GA; Sacco O; Capizzi A; Mastromarino P
Front Immunol; 2021; 12():670955. PubMed ID: 34093569
[TBL] [Abstract][Full Text] [Related]
2. Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19.
Marinella MA
Int J Clin Pract; 2020 Sep; 74(9):e13535. PubMed ID: 32412158
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol and Pterostilbene Inhibit SARS-CoV-2 Replication in Air-Liquid Interface Cultured Human Primary Bronchial Epithelial Cells.
Ter Ellen BM; Dinesh Kumar N; Bouma EM; Troost B; van de Pol DPI; van der Ende-Metselaar HH; Apperloo L; van Gosliga D; van den Berge M; Nawijn MC; van der Voort PHJ; Moser J; Rodenhuis-Zybert IA; Smit JM
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372541
[TBL] [Abstract][Full Text] [Related]
5. Flavonoids against the SARS-CoV-2 induced inflammatory storm.
Liskova A; Samec M; Koklesova L; Samuel SM; Zhai K; Al-Ishaq RK; Abotaleb M; Nosal V; Kajo K; Ashrafizadeh M; Zarrabi A; Brockmueller A; Shakibaei M; Sabaka P; Mozos I; Ullrich D; Prosecky R; La Rocca G; Caprnda M; Büsselberg D; Rodrigo L; Kruzliak P; Kubatka P
Biomed Pharmacother; 2021 Jun; 138():111430. PubMed ID: 33662680
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms Underlying Potential Therapeutic Approaches for COVID-19.
Benani A; Ben Mkaddem S
Front Immunol; 2020; 11():1841. PubMed ID: 32793246
[TBL] [Abstract][Full Text] [Related]
7. Can Natural Polyphenols Help in Reducing Cytokine Storm in COVID-19 Patients?
Giovinazzo G; Gerardi C; Uberti-Foppa C; Lopalco L
Molecules; 2020 Dec; 25(24):. PubMed ID: 33322757
[TBL] [Abstract][Full Text] [Related]
8. Promising drug repurposing approach targeted for cytokine storm implicated in SARS-CoV-2 complications.
Shawki MA; Elsayed NS; Mantawy EM; Said RS
Immunopharmacol Immunotoxicol; 2021 Aug; 43(4):395-409. PubMed ID: 34057871
[TBL] [Abstract][Full Text] [Related]
9. COVID-19: Some clinical questions after the first 4 months.
Bassetti M; Ansaldi F; Icardi G; Pelosi P; Robba C; Taramasso L; Trucchi C; Vena A; Giacobbe DR
Eur J Clin Invest; 2020 Jul; 50(7):e13326. PubMed ID: 32562550
[No Abstract] [Full Text] [Related]
10. Comprehensive Landscape of Heparin Therapy for COVID-19.
Shi C; Tingting W; Li JP; Sullivan MA; Wang C; Wang H; Deng B; Zhang Y
Carbohydr Polym; 2021 Feb; 254():117232. PubMed ID: 33357843
[TBL] [Abstract][Full Text] [Related]
11. A Network-Based Analysis Reveals the Mechanism Underlying Vitamin D in Suppressing Cytokine Storm and Virus in SARS-CoV-2 Infection.
Ahmed F
Front Immunol; 2020; 11():590459. PubMed ID: 33362771
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of resveratrol against emerging respiratory viral infections.
Filardo S; Di Pietro M; Mastromarino P; Sessa R
Pharmacol Ther; 2020 Oct; 214():107613. PubMed ID: 32562826
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory agents as potential therapeutic or preventive strategies for COVID-19.
Gaziano R; Pistoia ES; Campione E; Fontana C; Marino D; Favaro M; Pica F; Di Francesco P
Eur Rev Med Pharmacol Sci; 2021 Jun; 25(11):4174-4184. PubMed ID: 34156699
[TBL] [Abstract][Full Text] [Related]
14. Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19.
Al-Kuraishy HM; Al-Gareeb AI; Mostafa-Hedeab G; Kasozi KI; Zirintunda G; Aslam A; Allahyani M; Welburn SC; Batiha GE
Front Immunol; 2021; 12():749291. PubMed ID: 34867978
[TBL] [Abstract][Full Text] [Related]
15. Phenylmethimazole is a candidate drug for the treatment of severe forms of coronavirus disease 2019 (COVID-19) as well as other virus-induced "cytokines storm".
Giuliani C; Bucci I; Napolitano G
Med Hypotheses; 2021 Jan; 146():110473. PubMed ID: 33385879
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 and inflammatory bowel disease: A pathophysiological assessment.
Yang C; Xiao SY
Biomed Pharmacother; 2021 Mar; 135():111233. PubMed ID: 33433350
[TBL] [Abstract][Full Text] [Related]
17. Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation.
Tufan A; Matucci-Cerinic M
Turk J Med Sci; 2021 Dec; 51(SI-1):3391-3404. PubMed ID: 34844296
[TBL] [Abstract][Full Text] [Related]
18. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
[TBL] [Abstract][Full Text] [Related]
19. Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management.
Anka AU; Tahir MI; Abubakar SD; Alsabbagh M; Zian Z; Hamedifar H; Sabzevari A; Azizi G
Scand J Immunol; 2021 Apr; 93(4):e12998. PubMed ID: 33190302
[TBL] [Abstract][Full Text] [Related]
20. AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine storm.
Gangemi S; Tonacci A
Cytokine Growth Factor Rev; 2021 Apr; 58():111-113. PubMed ID: 32938545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
